Chinese Medical Journal, 2018 Background: There was still conflict on the antithrombotic advantage of ticagrelor versus clopidogrel among East Asian population with acute coronary syndrome (ACS).
He-Yang Wang +4 more
doaj +1 more source
Investigação recente em antitrombóticos. Novidades para o tratamento dos doentes com síndromas coronárias agudas [PDF]
, 2010 A terapêutica antitrombótica ocupa um lugar central no tratamento da doença coronária aguda. A sua importância foi reforçada com a generalização dos procedimentos de intervenção percutânea, em especial quando são implantados dispositivos intra-coronários.
Morais, João
core
Design and Rationale for comParison Between ticagreLor and clopidogrEl on mIcrocirculation in Patients with Acute cOronary Syndrome Undergoing Percutaneous Coronary Intervention (PLEIO) Trial [PDF]
, 2018 Kyungil Park +5 more
openalex +1 more source
Ticagrelor versus clopidogrel in the management of acute myocardial infarction
Journal of Community Hospital Internal Medicine Perspectives, 2019 Hypothesis: In the care of acute myocardial infarction, ticagrelor attenuates post-ischemic myocardial damage and inhibits platelet activity to a greater extent than clopidogrel.
Candice Volney +2 more
doaj +1 more source
Ticagrelor-Pretreated Cardiomyocyte Derived Exosomes Provide Cardioprotection Under Hyperglycemia Through Alleviation In Oxidative Stress, Apoptosis, And ER-Stress [PDF]
, 2021 Ceylan Verda Bitirim +6 more
openalex +1 more source
Consolidation of P2Y12 Testing While Maintaining Quality and Turnaround Time [PDF]
, 2017 Objective: To consolidate the test performed at 2 different locations at 1, thereby improving cost effectiveness while maintaining quality and result turnaround time.https://jdc.jefferson.edu/patientsafetyposters/1059/thumbnail ...
Gong, MD, Jerald Z. +1 more
core +1 more source
Ticagrelor as an Alternative for Clopidogrel-Associated Acute Arthritis [PDF]
, 2018 Starr-Mar’ee C. Bedy +2 more
openalex +1 more source
Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis
Drug Design, Development and Therapy, 2016 Michael R Preusch,1 Jonas Rusnak,1 Kathrin Staudacher,2 Carolin Mogler,3 Lorenz Uhlmann,4 Philipp Sievers,1 Florian Bea,1 Hugo A Katus,1 Erwin Blessing,1 Ingo Staudacher1 1Department of Internal Medicine III, 2Department of Neonatology, 3Department of ...
Preusch MR +9 more
doaj
Utilización de antiagregantes plaquetarios en el Síndrome Coronario Agudo [PDF]
, 2018 Introducción. El síndrome coronario agudo está considerado una de las principales causas de muerte actualmente. Se han realizado muchos avances farmacológicos en dicha patología, por ello es necesario realizar estudios de adecuación de los nuevos ...
Martín Muñoz, Daniel
core